4[2]Hayreh SS, klygman MR, Beri M, et al. Differentiation of ischemic from nonischenic central retinal vein occlusion during the early acute phase. Graefs Arch Clin Exp Ophthahmal, 1990, 228:201～217.
5Michael L, Murat T, John K, et al. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmology, 2002, 109: 126-131.
6Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb,2002, 32(5-6) :308-311.
7Prisco D, Marcucci R, Bertini L, et al. Cardiovascular and thrombophilic risk factors for central retinal vein occlusion. Eur J Intern Med, 2002, 13:163-169.
8Lahey JM, Kearney JJ, Tunc M. Hypercoagulable states and central retinal vein occlusion. Curr Opin Pulm Med, 2003, 9:385-392.
9Van Cott EM, Laposata M, Hartnett ME. Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis. Blood Coagul Fibrinolysis, 2004, 15:393-397.
10Marcucci R, Bertini L, Giusti B, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost,2001, 86:772-776.
